Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial

Clin Infect Dis. 2018 Jun 1;66(12):1953-1956. doi: 10.1093/cid/cix1051.

Abstract

In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Benzoxazines / blood
  • Benzoxazines / metabolism*
  • Black or African American
  • Cohort Studies
  • Coinfection / drug therapy
  • Coinfection / ethnology
  • Coinfection / virology
  • Cyclopropanes
  • Cytochrome P-450 CYP2B6 / genetics*
  • Drug Therapy, Combination
  • Female
  • Fluorenes / therapeutic use*
  • Genome-Wide Association Study
  • Genotype
  • HIV Infections / drug therapy
  • HIV Infections / ethnology
  • Hepacivirus / drug effects
  • Hepatitis C / drug therapy*
  • Hepatitis C / ethnology
  • Hepatitis C / genetics
  • Humans
  • Male
  • Polymorphism, Single Nucleotide
  • Recurrence
  • Sofosbuvir / therapeutic use*

Substances

  • Alkynes
  • Antiviral Agents
  • Benzimidazoles
  • Benzoxazines
  • Cyclopropanes
  • Fluorenes
  • ledipasvir
  • CYP2B6 protein, human
  • Cytochrome P-450 CYP2B6
  • efavirenz
  • Sofosbuvir